Evidence map›Paper›PMID 42079942›Full record

ArticleJTCVS open2026

Feasibility and oncologic outcomes of minimally invasive surgery after induction chemoimmunotherapy for non-small cell lung cancer.

Giovanni M Comacchio, Marisa Sewell, Kay See Tan, Nicolas Toumbacaris, Matthew J Bott, Prasad S Adusumilli, Alexis Chidi, Katherine Gray, James Huang, James M Isbell and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Giovanni M ComacchioThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Marisa SewellThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Kay See TanDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Nicolas ToumbacarisDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Matthew J BottThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Prasad S AdusumilliThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Alexis ChidiThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Katherine GrayThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
James HuangThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
James M IsbellThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Bernard J ParkThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Gaetano RoccoThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Valerie W RuschThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Smita SihagThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
David R JonesThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Daniela MolenaThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Objective: We evaluated the feasibility and long-term outcomes of minimally invasive surgery (MIS) after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer (NSCLC). Methods: Patients with stage IB-IIIB NSCLC who underwent induction immunotherapy followed by surgery (2015-2022) were included. Overall and event-free survival were estimated using the Kaplan-Meier approach. Cox regression was used to quantify associations between clinical and pathologic variables and survival outcomes. Results: In total, 69 patients met the inclusion criteria (MIS, n = 38; open surgery, n = 31). Patients who underwent open surgery had larger tumors ( Conclusions: MIS after induction immunotherapy is feasible and does not compromise long-term oncologic outcomes.

Indexed as

immunotherapyinduction therapyminimally invasive surgerynon–small cell lung cancer

Identifiers

PMID42079942
PMCPMC13131113

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.